2nd Annual Market Access Oncology Forum, 16-17 October 2012, SpainMain Category: Conferences
Article Date: 18 Sep 2012
Accessing the market with a product value story
With the government trying to cut down the costs on health spending, market access for oncology therapeutics is becoming more complicated and difficult. On the other hand, oncology medications, which are usually considered to be especially innovative, are increasing in demand.
There is a need for industry, regulation and payers to find the best way of meeting demands on both sides and create a better and faster way of collaboration in order to meet the ultimale goal - patient access to innovative medications.
Therefore, Fleming Europe has organised its:
2nd Annual MARKET ACCESS ONCOLOGY FORUM
16 - 17 October 2012, Spain
"It was a great opportunity to network, hear practical implementation examples, see vendor updates and take away new ideas what was just outstanding."
Oncology Market Access Manager, Pfizer
After the great success of the last year's event, this time we are coming to the City of Modernism, Barcelona.
20 expert speakers from pharma companies such as Celgene, Merck Serono, Amgen, J&J and non-industry speakers from INFARMED, HAS - SANTE, The World Bank, OECD and European Cancer Patient Coalition, will bring their valuable insights into the health care policy developments where the oncology market is maturing and access is increasingly restricted.
8 presentations, 2 special insights, 7 case studies and 4 focused discussions will reveal the future drivers in oncology in order to customise the product value story and compete for premium reimbursement.
Representatives from the World Bank and OECD will bring special insights. Focusing on Adaptation to new global market realities, Mr Andreas Seiter, Senior Health Specialist in Pharmaceuticals, the World Bank, will introduce global pricing & reimbursement trends for oncology medications and advise how to make pricing & reimbursement decisions more effective. He will talk about the healthcare policy reforms, point out differences among the countries and try to answer how much we are going to pay for oncology medications in the future and who will be footing the bill.
Ms Annalisa Belloni, Project Manager at OECD, will present organisation's project on Pharmaceutical value-based pricing. How do OECD countries assess the value of new medications? How much are they willing to pay for it? Are cancer drugs treated differently? Answers to these and many other questions of your interest will be revealed during the presentation.
The first day of the event will be concluded with EUnetHTA hot-spot discussion. Mr Miguel Gomes, Vice President of INFARMED, Portugal, Mr Francois Meyer, Advisor to the President, International Affairs, HAS - SANTE, France, and representatives of NICE and AIFA, will focus on the recent HTA developments in Europe & its impact on oncology market access. They will also offer recommendations & useful tips for industry on a successful launch of new medicine in HTA environment
On the second conference day, representatives of Amgen, Baxter, Novartis, Bayer, Bristol Myers Squibb and J&J will introduce Innovating market access models for oncology. In the form of case studies integrated market access strategies, homecare programs in oncology, utilisation of risk-sharing schemes, optimal indication sequencing as a tool for a successful market access and recent running programs will be described.
By joining this 2-day conference attendees will learn how to:
Original article posted on Medical News Today.
Articles not to be reproduced without permission of Medical News Today